Sun Pharma to Present 14 Abstracts at AAD 2026, Highlights Dermatology Pipeline

Sun Pharmaceutical Industries will present 14 abstracts at the American Academy of Dermatology Annual Meeting 2026, scheduled from March 27 to March 31,in Denver, US, the company said in a press release.

The presentations span psoriasis, alopecia areata and acne, reinforcing its focus on dermatology and immunology and its commitment to advancing treatment outcomes, it added

Among key highlights, data on ILUMYA showed sustained efficacy and safety in moderate-to-severe psoriasis, including nail involvement, with benefits observed over 52 weeks and supported by real-world evidence.

Pooled data from trials of LEQSELVI in alopecia areata indicated early scalp hair regrowth from Week 8, with continued improvement over time. The findings also highlighted gaps in patient and clinician alignment on treatment goals.

In acne treatment, a 52-week study of WINLEVI demonstrated a progressive reduction in sebum production and acne severity, supporting its role in targeting the androgen-sebum pathway. The company added that combination approaches may further enhance outcomes.

Sun Pharma said it will also engage clinicians through interactive sessions at the event, showcasing its dermatology and immunology portfolio.